Engagement in Upcoming Investor Conferences
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is gearing up for a series of important investor conferences scheduled for September. As a clinical-stage biotechnology company at the forefront of cell therapy aimed at treating autoimmune diseases, Cartesian's participation is highly anticipated.
Conference Details
The Company's management has outlined a promising schedule for the upcoming month, focusing on fostering dialogue with investors and sharing insights into their innovative therapeutic approaches. Here’s a closer look at the events they plan to participate in:
Cantor Global Healthcare Conference
An engaging fireside chat is set for Thursday, September 4, where Cartesian Therapeutics will discuss its progress and vision. This session, starting at 11:30 a.m. ET, offers stakeholders a rare opportunity to connect with the team and understand their strategic direction.
Morgan Stanley’s Annual Healthcare Conference
Following the Cantor event, Cartesian will also host a fireside chat on Tuesday, September 9, beginning at 4:05 p.m. ET. This platform will further delve into the Company’s groundbreaking work and future endeavors within the biotechnology landscape.
H.C. Wainwright Global Investment Conference
The last of the trio of significant events will be a presentation at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, at 8:30 a.m. ET. This conference is renowned for uniting leading biotechnology companies and providing them with a stage to present their innovations and financial outlooks.
Accessing the Presentations
All live-streamed sessions of these discussions will be made available on Cartesian Therapeutics’ official website, allowing investors and interested parties to engage in real-time. Additionally, an archived replay of the discussions will also be accessible on the site for those who want to revisit the insights shared.
About Cartesian Therapeutics
Cartesian Therapeutics stands as a pioneering entity in the field of biotechnology, particularly in the realm of autoimmune disease therapies. Their flagship product, Descartes-08, is currently undergoing Phase 3 clinical trials for patients with generalized myasthenia gravis, as well as Phase 2 development for systemic lupus erythematosus. Furthermore, a Phase 2 basket trial is in the works for additional autoimmune conditions, reflecting the Company's commitment to broadening its impact.
Additionally, Cartesian’s R&D pipeline includes Descartes-15, an innovative CAR-T therapy that is currently in a Phase 1 trial for patients diagnosed with multiple myeloma. This underscores the Company's dedication to advancing therapeutic options for a variety of challenging health issues.
Keeping Informed
To stay updated on Cartesian Therapeutics' developments, investors can follow the Company on social media platforms such as LinkedIn and X, formerly known as Twitter. This engagement opens avenues for continuous dialogue and information exchange, crucial in the fast-evolving biotechnology sector.
Contact Information for Investors and Media
For any inquiries, investors can reach out to Megan LeDuc, Associate Director of Investor Relations, at megan.leduc@cartesiantx.com. Media inquiries can be directed to David Rosen at Argot Partners via email at david.rosen@argotpartners.com.
Frequently Asked Questions
What is Cartesian Therapeutics known for?
Cartesian Therapeutics specializes in pioneering cell therapies aimed at treating autoimmune diseases, with a focus on innovative treatment approaches.
What events will Cartesian participate in?
Cartesian is set to engage in the Cantor Global Healthcare Conference, Morgan Stanley’s Annual Healthcare Conference, and the H.C. Wainwright Global Investment Conference.
How can I access the presentations from the conferences?
Live webcasts and archived presentations will be available on the Company’s official website.
What is the significance of Descartes-08?
Descartes-08 represents a leading asset in Cartesian's portfolio, currently undergoing advanced clinical trials for its efficacy in treating specific autoimmune conditions.
Who can I contact for investor-related questions?
Investors can contact Megan LeDuc at megan.leduc@cartesiantx.com for any inquiries or further information.
